[124]
For the Reasons provided herein
:
THE COURT ADJUDGES that:
1. Section 8 of the
Patented Medicines (Notice of Compliance) Regulations
SOR/93-133 as amended (SOR/98-166) effective until 2006 is:
a. within the competence of the Federal Court to hear and determine an action brought thereunder;
b. enabled by the
Patent
Act
, R.S.C. 1985, c. P-4 as amended S.C. 1993, c. 2, s. 4; and
c. intra vires the constitutional authority of the federal Parliament of Canada
2. In this action brought under the provisions of said section 8:
a. Apotex Inc. is not entitled to elect an account or the disgorgement of the profits of the Respondent, Merck Frosst Canada Ltd. or Merck Frosst Canada & Co.;
b. Apotex Inc. is entitled to claim damages or its lost profits for the period from February 3, 2004 to May 26, 2005; and
c. Apotex Inc. is entitled to claim damages for lost sales and lost permanent market share as claimed in paragraphs 1 (a)(ii) of its Further Amended Statement of Claim dated October 6, 2008 for a period beyond May 26, 2005 provided it is shown in evidence that such loss was not rectified and could not have been rectified before that date;
3. The quantification of the damages or lost profits referred to in paragraph 2 above shall be the subject of the further trial as set out in the Order of this Court dated August 14, 2008. Any party is entitled to seek case management by the Prothonotary assigned to this action for directions as to the procedure to be followed in respect of said trial;
4. No party is entitled to costs of this present portion of the trial of this action.
Order accordingly.